GNRH1 and venous thromboembolism: Additionally, a British study including 11 199 men with advanced prostate cancer showed that patients treated with cyproterone acetate had a significantly higher risk for venous thromboembolism than did men who underwent orchiectomy or were prescribed GNRH agonists (adjusted odds ratio 5·23, 95% CI 3·12–8·79).7